Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.3
1.9
Journals
Tomography
Special Issues
Advances in the Radiography of Prostate Cancer
share announcement

Advances in the Radiography of Prostate Cancer

A special issue of Tomography (ISSN 2379-139X).

Deadline for manuscript submissions: closed (30 December 2022) | Viewed by 10202

Special Issue Editor

Dr. Tore Bach-Gansmo

E-Mail Website
Guest Editor
Department of Radiology and Nuclear Medicine, University Hospital of North Norway, 9019 Tromsø, Norway
Interests: PET-CT; prostate cancer

Special Issue Information

Dear Colleagues, 

Today, PET/CT has a profound influence on diagnostic work in prostate cancer, where MR alone was the leading technology for a decade. Today, multimodality imaging is striving to find the correct balance between cost and benefit. The possibility of PET/MR has not, or not yet, resulted in a major change to this modality. This may be due both to the relative paucity of PET/MR and inherent difficulties in the technology.

On top of technological advances, we can observe a multitude of other possibilities that are invading our field. A number of PET tracers are used or under development. An impressive number of PSMA analogues, based on generator-based 67Ga-gallium or cyclotron-based 18F-flour, are under development. The last word on their respective sensitivity and specificity has not yet been uttered.

Not least, the new treatment possibility with protein receptor radionuclides has produced amazing results in clinical trials, and they are on the verge of marketing authorization, possibly changing the prognosis of a vast number of patients.

There is a plentitude of potential new knowledge, leaving us with a number of stones unturned, hence this Special Issue.

Papers of high academic standard addressing these and related topics are invited to this Special Issue. We are looking for results from clinical and preclinical studies and papers identifying unmet needs or challenges related to the field of imaging and nuclear-medicine-based therapeutics.

Dr. Tore Bach-Gansmo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Tomography is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • MR
  • PET/MR
  • PET/CT
  • F/Ga-PSMA
  • PSMA therapeutic use
  • FDG
  • FACBC

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 2368 KiB  
Article
[18F]fluciclovine vs. [18F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients
by Cristina Ferrari, Paolo Mammucci, Valentina Lavelli, Antonio Rosario Pisani, Anna Giulia Nappi, Dino Rubini, Angela Sardaro and Giuseppe Rubini
Tomography 2022, 8(6), 2709-2722; https://0-doi-org.brum.beds.ac.uk/10.3390/tomography8060226 - 05 Nov 2022
Cited by 5 | Viewed by 1468
Abstract
Nowadays, there is still no consensus on the most accurate PET radiopharmaceutical to early detect prostate cancer (PCa) relapse. A tailored radiotracer choice based on a specific patient’s profile could ensure prompt disease detection and an improvement in patients management. We aimed to [...] Read more.
Nowadays, there is still no consensus on the most accurate PET radiopharmaceutical to early detect prostate cancer (PCa) relapse. A tailored radiotracer choice based on a specific patient’s profile could ensure prompt disease detection and an improvement in patients management. We aimed to compare the [18F]fluciclovine and [18F]fluorocholine PET/CT detection rate (DR) in PCa patients restaged for early biochemical recurrence (BCR), according to clinical and biochemical features. A cohort of 138 PCa patients with early BCR (mean age: 71 y, range: 50–87 y) were homogeneously randomized 1:1 to a [18F]fluciclovine or a [18F]fluorocholine PET/CT group. The respective PET/CT DR, according to per-patient and per-region analysis, and the impact of the biochemical, clinical, and histological parameters, were compared. The PSA cut-off values predictive of a positive scan were also calculated. Overall, the [18F]fluciclovine PET/CT DR was 64%, significantly higher than the [18F]fluorocholine PET/CT DR of 35% (p = 0.001). Similarly, in the per-region analysis, the [18F]fluciclovine PET/CT DR was 51% in the prostate region, significantly higher compared to 15% of [18F]fluorocholine (p < 0.0001). Furthermore, a statistically significant higher DR in per-patient and per-region (prostate/prostate bed) analysis was observed in the [18F]fluciclovine group for 0.5–1 ng/mL (p = 0.018, p = 0.049) and >1 ng/mL (p = 0.040, p < 0.0001) PSA values. A PSA of 0.45 ng/mL for [18F]fluciclovine and of 0.94 ng/mL for [18F]fluorocholine was identified as the optimal cut-off value in predicting a positive PET/CT scan. Our results demonstrated a better [18F]fluciclovine PET/CT DR compared to [18F]fluorocholine for restaging PCa patients in early BCR, particularly in the detection of locoregional recurrence. The significantly higher [18F]fluciclovine DR for low PSA values (PSA < 1 ng/mL) supports its use in this setting of patients. Full article
(This article belongs to the Special Issue Advances in the Radiography of Prostate Cancer)
►▼ Show Figures

Figure 1

8 pages, 330 KiB  
Article
Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
by Tore Bach-Gansmo, Katrine Korsan and Trond Velde Bogsrud
Tomography 2022, 8(3), 1477-1484; https://0-doi-org.brum.beds.ac.uk/10.3390/tomography8030120 - 03 Jun 2022
Cited by 1 | Viewed by 2953
Abstract
Background: 18F-fluciclovine is a positron emission tomography (PET) radiotracer approved for the detection of prostate cancer recurrence. No effect of androgen deprivation therapy (ADT) on its performance has been established. Purpose: To study the impact of concurrent ADT on disease detection with 18F-fluciclovine [...] Read more.
Background: 18F-fluciclovine is a positron emission tomography (PET) radiotracer approved for the detection of prostate cancer recurrence. No effect of androgen deprivation therapy (ADT) on its performance has been established. Purpose: To study the impact of concurrent ADT on disease detection with 18F-fluciclovine PET in patients with prostate cancer. Materials and Methods: Data from patients with prostate cancer who had been receiving ADT for ≥3 months at the time of undergoing an 18F-fluciclovine PET/CT at our institution were retrospectively reviewed. Seventy-three scans from 71 patients were included. The scans indicated rising prostate-specific antigen (n = 58), staging advanced disease (n = 4) or therapeutic monitoring (n = 9). Patients’ medical records provided baseline clinical data and post-scan outcomes (median follow-up 40 months). Results: Malignant lesions with increased uptake of 18F-fluciclovine were detected in 60/73 (82%) scans; 33 (45%) had lesions in the prostate/bed and 46 (63%) in extraprostatic sites. Patients received ADT for a median of 2 years (range 3 months to >10 years) pre-scan. The time on ADT did not influence detection; the detection rates were 89% for patients who had received ADT for <1 year, 63% for a treatment period of 1–<2 years, 83% for 2–4 years, 78% for >4–10 years, and 67% for a treatment period of >10 years. Conclusion: 18F-fluciclovine detected recurrent or metastatic lesions in 82% of patients with prostate cancer receiving ADT. The rates achieved in the present study are consistent with widely reported data for 18F-fluciclovine PET/CT, suggesting that withdrawal of ADT before scanning is not necessary. Full article
(This article belongs to the Special Issue Advances in the Radiography of Prostate Cancer)
►▼ Show Figures

Figure 1

7 pages, 226 KiB  
Communication
Diagnostic Performance of Preoperative Choline-PET/CT in Patients Undergoing Salvage Lymph Node Dissection for Recurrent Prostate Cancer: A Multicenter Experience
by Łukasz Nyk, Hubert Kamecki, Wojciech Krajewski, Bartosz Małkiewicz, Tomasz Szydełko, Markiian Kubis, Marcin Słojewski, Piotr Kryst, Sławomir Poletajew and Wojciech Malewski
Tomography 2022, 8(2), 1090-1096; https://0-doi-org.brum.beds.ac.uk/10.3390/tomography8020089 - 11 Apr 2022
Cited by 1 | Viewed by 1436
Abstract
We aimed to retrospectively analyze consecutive prostate cancer patients diagnosed with biochemical or clinical recurrence after local treatment with curative intent, with no evidence of distant metastases, who underwent positron emission tomography/computed tomography (PET/CT) with choline followed by salvage lymph node dissection (SLND) [...] Read more.
We aimed to retrospectively analyze consecutive prostate cancer patients diagnosed with biochemical or clinical recurrence after local treatment with curative intent, with no evidence of distant metastases, who underwent positron emission tomography/computed tomography (PET/CT) with choline followed by salvage lymph node dissection (SLND) in three academic centers between 2013 and 2020. A total of 27 men were included in the analyses. Sensitivity, specificity, positive and negative predictive values, and accuracy of choline-PET/CT in predicting pathology-proven lymph node involvement were 75%, 43%, 79%, 38% and 67% on per-patient and 70%, 86%, 80%, 78%, and 79% on per-site analyses, respectively, with the differences in specificity and NPV between per-patient and per-site analyses being statistically significant (p = 0.03 and 0.04, respectively). The study provides further insight into the role of preoperative choline-PET/CT in patients undergoing SLND for recurrent PC. Full article
(This article belongs to the Special Issue Advances in the Radiography of Prostate Cancer)

Review

Jump to: Research

14 pages, 10018 KiB  
Review
Application of Hydrogel Spacer SpaceOAR Vue for Prostate Radiotherapy
by Satvik R. Hadigal and Atul K. Gupta
Tomography 2022, 8(6), 2648-2661; https://0-doi-org.brum.beds.ac.uk/10.3390/tomography8060221 - 27 Oct 2022
Cited by 7 | Viewed by 3789
Abstract
Damage in the surrounding structures, including the rectum, due to unintended exposure to radiation is a large burden to bear for patients who undergo radiation therapy for prostate cancer. The use of injectable rectal spacers to distance the anterior rectum from the prostate [...] Read more.
Damage in the surrounding structures, including the rectum, due to unintended exposure to radiation is a large burden to bear for patients who undergo radiation therapy for prostate cancer. The use of injectable rectal spacers to distance the anterior rectum from the prostate is a potential strategy to reduce the dose of unintended radiation to the rectum. Hydrogel spacers are gaining increasing popularity in the treatment regimen for prostate cancer. After FDA approval of SpaceOAR, specialists are receiving an increasing number of referrals for hydrogel placements. In this paper, we review hydrogel spacers, the supporting clinical data, the best practices for hydrogel placement, and the risk of adverse events. Full article
(This article belongs to the Special Issue Advances in the Radiography of Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop